These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20856239)

  • 1. Is P-glycoprotein involved in amyloid-β elimination across the blood-brain barrier in Alzheimer's disease?
    Ohtsuki S; Ito S; Terasaki T
    Clin Pharmacol Ther; 2010 Oct; 88(4):443-5. PubMed ID: 20856239
    [No Abstract]   [Full Text] [Related]  

  • 2. MDR1-P-glycoprotein (ABCB1)-mediated disposition of amyloid-β peptides: implications for the pathogenesis and therapy of Alzheimer's disease.
    Jedlitschky G; Vogelgesang S; Kroemer HK
    Clin Pharmacol Ther; 2010 Oct; 88(4):441-3. PubMed ID: 20856238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-brain barrier P-glycoprotein function in Alzheimer's disease.
    van Assema DM; Lubberink M; Bauer M; van der Flier WM; Schuit RC; Windhorst AD; Comans EF; Hoetjes NJ; Tolboom N; Langer O; Müller M; Scheltens P; Lammertsma AA; van Berckel BN
    Brain; 2012 Jan; 135(Pt 1):181-9. PubMed ID: 22120145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations.
    Chiu C; Miller MC; Monahan R; Osgood DP; Stopa EG; Silverberg GD
    Neurobiol Aging; 2015 Sep; 36(9):2475-82. PubMed ID: 26159621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier.
    Kuhnke D; Jedlitschky G; Grube M; Krohn M; Jucker M; Mosyagin I; Cascorbi I; Walker LC; Kroemer HK; Warzok RW; Vogelgesang S
    Brain Pathol; 2007 Oct; 17(4):347-53. PubMed ID: 17610523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.
    Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN
    Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of insulin-degrading enzyme in insulin- and atrial natriuretic peptide-sensitive internalization of amyloid-β peptide in mouse brain capillary endothelial cells.
    Ito S; Ohtsuki S; Murata S; Katsukura Y; Suzuki H; Funaki M; Tachikawa M; Terasaki T
    J Alzheimers Dis; 2014; 38(1):185-200. PubMed ID: 23948938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transport of Alzheimer disease amyloid-beta-binding D-amino acid peptides across an in vitro blood-brain barrier model.
    Liu H; Funke SA; Willbold D
    Rejuvenation Res; 2010; 13(2-3):210-3. PubMed ID: 19954305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
    Shackleton B; Crawford F; Bachmeier C
    Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation.
    Boado RJ; Zhang Y; Zhang Y; Xia CF; Pardridge WM
    Bioconjug Chem; 2007; 18(2):447-55. PubMed ID: 17315944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ability of carbazole salts, inhibitors of Alzheimer beta-amyloid fibril formation, to cross cellular membranes.
    Saengkhae C; Salerno M; Adès D; Siove A; Le Moyec L; Migonney V; Garnier-Suillerot A
    Eur J Pharmacol; 2007 Mar; 559(2-3):124-31. PubMed ID: 17291491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Amyloidogenicity and pathogenicity of Abeta43 in Alzheimer's disease].
    Saito T
    Seikagaku; 2013 Jul; 85(7):543-52. PubMed ID: 23980468
    [No Abstract]   [Full Text] [Related]  

  • 13. Amyloid-β concentration and structure influences the transport and immunomodulatory effects of IVIG.
    Wuest DM; Lee KH
    J Neurochem; 2014 Jul; 130(1):136-44. PubMed ID: 24517534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aβ(1-42) disrupts the expression and function of KLF2 in Alzheimer's disease mediated by p53.
    Wu C; Li F; Han G; Liu Z
    Biochem Biophys Res Commun; 2013 Feb; 431(2):141-5. PubMed ID: 23313511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease.
    DeMattos RB; O'dell MA; Parsadanian M; Taylor JW; Harmony JA; Bales KR; Paul SM; Aronow BJ; Holtzman DM
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10843-8. PubMed ID: 12145324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro discrimination of the role of LRP1 at the BBB cellular level: focus on brain capillary endothelial cells and brain pericytes.
    Candela P; Saint-Pol J; Kuntz M; Boucau MC; Lamartiniere Y; Gosselet F; Fenart L
    Brain Res; 2015 Jan; 1594():15-26. PubMed ID: 25451130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine for the treatment of Alzheimer's disease.
    Gregori M; Masserini M; Mancini S
    Nanomedicine (Lond); 2015; 10(7):1203-18. PubMed ID: 25929574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apical-to-basolateral transport of amyloid-β peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein.
    Candela P; Gosselet F; Saint-Pol J; Sevin E; Boucau MC; Boulanger E; Cecchelli R; Fenart L
    J Alzheimers Dis; 2010; 22(3):849-59. PubMed ID: 20858979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of the blood-brain barrier in Alzheimer's disease].
    Gosselet F; Candela P; Cecchelli R; Fenart L
    Med Sci (Paris); 2011 Nov; 27(11):987-92. PubMed ID: 22130026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol decreases the insoluble Aβ1-42 level in hippocampus and protects the integrity of the blood-brain barrier in AD rats.
    Zhao HF; Li N; Wang Q; Cheng XJ; Li XM; Liu TT
    Neuroscience; 2015 Dec; 310():641-9. PubMed ID: 26454022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.